Frequency of Inhibitors Among Known Haemophilia A Patients

Abstract

Background: Inhibitors are IgG alloantibodies which are directed against exogenous clotting factor VIII that
neutralize the function of infused clotting factor concentrate used for the treatment. The prevalence of
inhibitors in Hemophilia A is around 30% worldwide. Inhibitors occur as a result of natural immune process
of the body as factor concentrates used for treatment are foreign to the body and patient's own body either
produces no factor or produces structurally abnormal protein. The objective of this study is to determine the
frequency of inhibitors among known hemophilia Apatients.
Methods: Cross-sectional survey done including 100 male patients of hemophilia A and on treatment for
more than 1 year, from 2 to 60 years of age. All the patients were undergone aPTT based screening for
inhibitor, both immediately and two hours after mixing the patients plasma with the normal plasma.
Results: Age range in this study was from 2 to 60 years with mean age of 37.21 ± 14.73 years. Frequency of
inhibitors among known hemophilia Apatients was 18 (18.0%) of cases.
Conclusion: Frequency of inhibitors among known hemophilia Apatients is considerably high